Gilead briefing documents 'benign' as expected, says Maxim

theflyonthewall.com

Maxim said the FDA panel briefing documents for Gilead's hepatitis C candidate sofosbuvir are "benign" as expected. The firm expects a launch in 2014 and keeps a Buy rating on the stock.

View Comments